SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Fancy who wrote (4117)4/21/1998 12:47:00 PM
From: Izzy  Read Replies (3) of 6136
 
Steve, thanks for the detailed post. Can't figure out why MS has downgraded the stock and has lowered the 12 mos target price to the low 40s from the previous target in the 60s. I think that Viracept is approaching 40% of the market share of protease inhibitors. However, there may be problems with the AGPH GART inhibitor (drug side-effects). Do you have any opinion when/if AGPH will break/stay above 40? How do you interpret the TA (charts)? Too bad AGPH doesn't have a drug like Viagra, which obviously has a wider appeal (for the public; not me, tho').
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News